Categories: Health

Philips to repurchase up to 6 million shares to cover long-term incentive plans

June 4, 2025 

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it will repurchase up to 6 million shares to cover certain of its obligations arising from its long-term incentive plans. At the current share price, the shares represent an amount of up to approximately EUR 125 million.

The repurchases will be executed through one or more individual forward transactions, to be entered into in the course of the second and third quarter of 2025, in accordance with the Market Abuse Regulation and within the limits of the authorization granted by the company’s General Meeting of Shareholders on May 8, 2025. Philips expects to take delivery of the shares in 2027. Further details will be available via this link.

For further information, please contact:
Michael Fuchs
Philips Global External Relations
Tel.: +31 6 1486 9261
E-mail: michael.fuchs@philips.com

Dorin Danu
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: dorin.danu@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

GlobeNews Wire

Recent Posts

NeuroDyne Drops: Sharp Mind, Enhanced Memory, and Lasting Focus As Nature Intended, Ingredients

NEURODYNE DROPS INTRODUCED AS A COGNITIVE WELLNESS SUPPLEMENT SUPPORTING HEALTHY MEMORY, FOCUS, AND MENTAL CLARITY…

2 hours ago

Optivell Officially Announced as a Vision Support Formula for Preventive Eye Wellness

New York City, NY, Jan. 17, 2026 (GLOBE NEWSWIRE) -- OPTIVELL INTRODUCED AS A NEW…

2 hours ago

Sugar Clean Drops: Top Blood Sugar Support Supplement for Metabolic Wellness and Energy Support

SUGAR CLEAN DROPS ANNOUNCED AS A NEW SUPPLEMENT SUPPORTING HEALTHY BLOOD SUGAR AND METABOLIC WELLNESS…

2 hours ago

DBV Technologies Announces 166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing

Châtillon, France, January 16, 2026 DBV Technologies Announces €166.7 Million in Gross Proceeds Following the…

13 hours ago

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2026 16:15 ET  | Source: Zenas BioPharma WALTHAM, Mass., Jan. 16, 2026 (GLOBE…

13 hours ago